Personalised treatments to improve seizure control.

Around 2% of people will develop epilepsy during their lifetime. Currently there are around 100,000 children and adults in Queensland with epilepsy. More than a third of patients don’t respond to current anti-epilepsy drugs.

This project will incorporate genomic testing into the model of care for patients with neurological disorders like refractory epilepsy.

This approach can provide patients and their families with a cause for the disorder, as well as an opportunity for better treatment choices suited to the patient.

The ultimate goal of this work is to improve the quality of care for patients and their families, and improve efficiencies in healthcare.

This is a clinical implementation project, which applies best evidence to clinical practice and is intended to become standard of care following project completion.

Project Investigators

Project leaders engage with and draw upon the expertise of partners within universities, research institutes and hospital and health services around Queensland.

Associate Professor Lata Vadlamudi, Metro North Hospital & Health Services and The University of Queensland (lead)

Professor David Reutens, Metro North Hospital & Health Services and The University of Queensland

Dr Cecilie Lander, Metro North Hospital & Health Services

Dr Alice-Ann Sullivan, Metro North Hospital & Health Services

Dr James Pelekanos, Metro North Hospital & Health Services

Dr Xiaochua Chen, Metro North Hospital & Health Services

Dr Kate Sinclair, Queensland Children’s Hospital

Dr Stephen Malone, Queensland Children’s Hospital

Dr Kate Riney, Queensland Children’s Hospital

Dr Sophie Calvert, Queensland Children’s Hospital

Dr Geoff Wallace, Queensland Children’s Hospital

Dr Adriane Sinclair, Queensland Children’s Hospital

Dr Ubaid Shah, Queensland Children’s Hospital

Dr Deepa Srinivasan, Queensland Children’s Hospital

Dr Ian Wilson, Cairns and Hinterland Hospital and Health Services

other whole of life projects